PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2005 | 3 | 1 | 72-81
Article title

Inclusion compounds of cystostatic active (C5H5)2VCl2 and (CH3C5H4)2VCl2 with α-, β- and γ-cyclodextrines: Synthesis, EPR study and microbiological behavior toward Escherichia coli

Content
Title variants
Languages of publication
EN
Abstracts
EN
The inclusion of vanadocene dichloride (VDC) and 1,1′-dimethyl vanadocene dichloride (MeVDC) into cyclodextrines (α-CD, β-CD and γ-CD) was studied by EPR spectroscopy. It was found that VDC and MeVDC with β-CD and γ-CD form true inclusion compounds, but with α-CD, VDC and MeVDC gave only fine dispersion mixtures. The inclusion was validated by anisotropic EPR spectra of solid samples. In addition, the antimicrobial was validated by anisotropic EPR spectra of solid samples. In addition, the antimicrobial behavior (against E. coli) of each of the complexes was determined. It was established that not only did VDC and MeVDC cause elongation of E. coli, but also the new vanadocene inclusion complexes were effective in this regard.
Publisher
Journal
Year
Volume
3
Issue
1
Pages
72-81
Physical description
Dates
published
1 - 3 - 2005
online
1 - 3 - 2005
References
  • [1] V.J. Moebus, R. Stein, D.G. Kieback, I.B. Runnebaum, G. Sass and R. Kreienberg: “Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives”, Anticancer Research, Vol. 17, (1997), pp. 815–821.
  • [2] G. Lümmen, H. Sperling, H. Luboldt, T. Otto and H. Rübben: “Phase II trial of titanocene dichloride in advanced renal-cell carcinoma”, Cancer Chemother. Pharmacol., Vol. 42, (1998), pp. 415–417. http://dx.doi.org/10.1007/s002800050838[Crossref]
  • [3] P. Köpf-Maier: “Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma”, Anticancer Research, Vol. 19, (1999), pp. 493–504.
  • [4] N. Kroger, U.R. Kleeberg, K. Mross, L. Edler, G. Sass and D.K. Hossfeld: “Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer”, Onkologic, Vol. 23, (2000), pp. 60–62. http://dx.doi.org/10.1159/000027075[Crossref]
  • [5] P. Köpf-Maier and H. Köpf: “Non-Platinum-Group Metal Antitumor Agents: History, Current Status, and Perspectives”, Chem. Rev., Vol. 87, (1987), pp. 1137–1152. http://dx.doi.org/10.1021/cr00081a012[Crossref]
  • [6] A. Harada and S. Takahashi: “Preparation and Properties of Cyclodextrin-Ferrocene Inclusion Complexes”, J. Chem. Soc.-Chem. Commun. (1984), pp. 645–646. [Crossref]
  • [7] A. Harada, Y. Hu, S. Yamamoto and S. Takahashi: “Preparation and Properties of Inclusion-Compounds of Ferrocene and Its Derivatives with Cyclodextrins”, J. Chem. Soc.-Dalton Trans., (1988), pp. 729–732. [Crossref]
  • [8] Y. Odagaki, K. Hirotsu, T. Higuchi, A. Harada and S. Takahashi: “X-Ray Structure of the α-Cyclodextrin Ferrocene (2-1) Inclusion Compound”, J. Chem. Soc.-Perkin Trans. 1, (1990), pp. 1230–1231. http://dx.doi.org/10.1039/p19900001230[Crossref]
  • [9] P. Ferreira, I.S. Goncalves, M. Pillinger, J. Rocha, P. Santos and J.J.C. Teixeira-Dias: “Modification of β-cyclodextrin with ferrocenyl groups by ring opening of an encapsulated 1 ferrocenophane”, Organometallics, Vol. 19 (2000), pp. 1455–1457. http://dx.doi.org/10.1021/om991033u[Crossref]
  • [10] S.S. Braga, I.S. Goncalves, A.D. Lopes, M. Pillinger, J. Rocha, C.C. Romao and J.J.C. Teixeira-Dias: “Encapsulation of half-sandwich complexes of molybdenum with beta-cyclodextrin”, J. Chem. Soc-Dalton Trans., (2000), pp. 2964–2968. [Crossref]
  • [11] S. Lima, I.S. Goncalves, P. Ribeiro-Claro, M. Pillinger, A.D. Lopes, P. Ferreira J.J.C. Teixeira-Dias, J. Rocha and C.C. Romao: “Interactions of cationic and neutral molybdenum complexes with β-cyclodextrin host molecules”, Organometallics, Vol. 20 (2001), pp. 2191–2197. http://dx.doi.org/10.1021/om001088s[Crossref]
  • [12] I. Turel, A. Demsar and J. Kosmrlj: “The interactions of titanocene dihalides with alpha-, beta- and gamma-cyclodextrin host molecules”, J. Incl. Phenom. Macrocycl. Chem., Vol. 35, (1999), pp. 595–604. http://dx.doi.org/10.1023/A:1008026715964[Crossref]
  • [13] C.S. Lu, Y. Zou, J.L. Xie, Z.P. Ni, H.Z. Zhu, Q.J. Meng and Y.G. Yao: “An antitumor agent of β-cyclodextrin-modified titanocene complex: Synthesis and characterization”, Chem. Pharm. Bull., Vol. 51 (2003), pp. 864–866. http://dx.doi.org/10.1248/cpb.51.864[Crossref]
  • [14] S.S. Braga, I.S. Gonçalves, M. Pillinger, P. Ribeiro-Claro and J.J.C. Teixeira-Dias: “Experimental and theoretical study of the interaction of molybdenocene dichloride (Cp2MoCl2) with β-cyclodextrin”, J. Organomet. Chem., Vol. 632, (2001), pp. 11–16. http://dx.doi.org/10.1016/S0022-328X(01)00836-1[Crossref]
  • [15] E. Fenyvesi, L. Szente, N.R. Russell and M. McNamara: Comprehensive Supramolecular Chemistry, J.L. Atwood, J.E.D. Davies, D.D. MacNicol, F. Vögtle, J.M. Lehn, J. Szejtli and T. Osa (Eds.), Pergamon, Oxford, 1996, Vol. 3, chap. 10.
  • [16] I. Pavlík and J. Vinklárek: “Hydrolysis Behavior of the Antitumor Agent Vanadocene Dichloride in Strongly Acid, Neutral and Alkaline Aqueous-Media-an EPR Study”, Eur. J. Solid State Inorg. Chem., Vol. 28, (1991), pp. 815–827.
  • [17] J. Honzíček, P. Nachtigall, I. Císařova and J. Vinklárek: “Synthesis, characterization and structural investigation of the first vanadocene(IV) carboxylic acid complexes prepared from the vanadocene dichloride”, J. Organomet. Chem., Vol. 689, (2004), pp. 1180–1187. http://dx.doi.org/10.1016/j.jorganchem.2003.11.042[Crossref]
  • [18] B. Rosenberg and L. van Camp: “The inhibition of grwoth and cell division in Escherichia coli)”, J. Biol. Chem., Vol. 242, (1967), pp. 1347–1352.
  • [19] I.C. Tornieporth-Oetting and P.S. White: “Ionic Titanocene(IV) α-Amino-Acid Complexes of Dl- Phenylalanine and Dl-4-Fluorophenylalanine-Synthesis, Characterization, and Investigation of the Antimicrobial Behavior toward Escherichia-Coli”, Organometallics, Vol. 14, (1995), pp. 1632–1636. http://dx.doi.org/10.1021/om00004a017[Crossref]
  • [20] E. Diana, R. Rossetti, P.L. Stanghellini and S.F.A. Kettle: “Vibrational study of (η 5-cyclopentadienyl) metal complexes”, Inorg. Chem., Vol. 36, (1997), pp. 382–391. http://dx.doi.org/10.1021/ic960545n[Crossref]
  • [21] J. Petersen and F. Dahl: “Synthesis and Structural Characterization by X-Ray Diffraction and Electron Paramagetic Resonance Single-Crystal Techniques of V(η 5-C5H4CH3)2Cl2 and Ti(η 5-C5H4CH3)2Cl2. A Study of the Distribution of the Unpaired Electron in a V(η 5-C5H5)2L2-Type Complex”, J. Am. Chem. Soc., Vol. 97, (1975), pp. 6422–6233. http://dx.doi.org/10.1021/ja00855a022[Crossref]
  • [22] P. Gowik and T. Klapötke: “Why Do Organometallic Hexafluoropnicogenate Complexes Show Biocidal Activity-a Study to the Structure Activity Correlation”, Monatshefte Für Chemie, Vol. 120, (1989), pp. 711–714. http://dx.doi.org/10.1007/BF00809962[Crossref]
  • [23] K. Mross, P. Robben-Bathe, L. Edler, J. Baumgart, W.E. Berdel, H. Fiebig and C. Unger: “Phase I clinical trial of a day-1,-3,-5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer-A study of the phase I study group of the Association for Medical Oncology (AIO) of the German Cancer Society”, Onkologie, Vol. 23, (2000), pp. 576–579. http://dx.doi.org/10.1159/000055009[Crossref]
  • [24] G. Wilkinson and J.M. Birmingham: “Bis-Cyclopentadienyl Compounds of Ti, Zr, V, Nb and Ta”, J. Am. Chem. Soc., Vol. 76, (1954), p. 4281. http://dx.doi.org/10.1021/ja01646a008[Crossref]
  • [25] J. Krzystek, A. Sienkiewicz, L. Pardi and L.C. Brunel: “DPPH as a Standard for High-Field EPR”, J. Magn. Reson., Vol. 125, (1997), pp. 207–211. http://dx.doi.org/10.1006/jmre.1996.1098[Crossref]
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_BF02476239
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.